Details of the Drug

General Information of Drug (ID: DM15P2G)

Drug Name

(5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol

Synonyms

Lificiguat; yc-1; 170632-47-0; 3-(5'-Hydroxymethyl-2'-furyl)-1-benzylindazole; YC 1; UNII-515CC1WPTE; Lificiguat(YC-1); 154453-18-6; [5-(1-benzyl-1h-indazol-3-yl)-2-furyl]methanol; 515CC1WPTE; CHEMBL333985; OQQVFCKUDYMWGV-UHFFFAOYSA-N; C19H16N2O2; 3-(5'-Hydroxymethyl-2'-furyl)-1-benzyl indazole; 1-Benzyl-3-(5-hydroxymethyl-2-furyl)indazole; [5-(1-benzyl-1H-indazol-3-yl)furan-2-yl]methanol; 5-[1-(Phenylmethyl)-1H-indazol-3-yl]-2-furanmethanol; YC-1

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

304.3

Logarithm of the Partition Coefficient (xlogp)

3.1

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

Chemical Identifiers

Formula: C19H16N2O2
IUPAC Name: [5-(1-benzylindazol-3-yl)furan-2-yl]methanol
Canonical SMILES: C1=CC=C(C=C1)CN2C3=CC=CC=C3C(=N2)C4=CC=C(O4)CO
InChI: InChI=1S/C19H16N2O2/c22-13-15-10-11-18(23-15)19-16-8-4-5-9-17(16)21(20-19)12-14-6-2-1-3-7-14/h1-11,22H,12-13H2
InChIKey: OQQVFCKUDYMWGV-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 5712
ChEBI ID: CHEMBL333985
CAS Number: 170632-47-0
TTD ID: D00REK

Drug-Molecule Activity Atlas (DMA)^NEW

Click to Jump to the Detailed DMA Information of This Drug

Drug Pharmacogenomic Perturbation (DPP)^NEW

Click to Jump to the Detailed DPP Information of This Drug

Drug ADMET Endpoint Profile (DAE)^NEW

Click to Jump to the Detailed DAE Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
HIF1-alpha messenger RNA (HIF1A mRNA)	TTSN6QU	HIF1A_HUMAN	Inhibitor	[2]
Soluble guanylate cyclase (GCS)	TT23PYC	GCYA1_HUMAN ; GCYB1_HUMAN	Activator	[3]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
cGMP-dependent protein kinase 1 (PRKG1)	OTPAS4LF	KGP1_HUMAN	Gene/Protein Processing	[4]
Cytochrome c (CYCS)	OTBFALJD	CYC_HUMAN	Protein Interaction/Cellular Processes	[5]
Mitogen-activated protein kinase 8 (MAPK8)	OTEREYS5	MK08_HUMAN	Gene/Protein Processing	[6]

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5291).
2	Synthesis of (aryloxyacetylamino)-isonicotinic/nicotinic acid analogues as potent hypoxia-inducible factor (HIF)-1alpha inhibitors. Bioorg Med Chem Lett. 2007 Nov 15;17(22):6305-10.
3	Activators of soluble guanylate cyclase for the treatment of male erectile dysfunction. Int J Impot Res. 2002 Feb;14(1):8-14.
4	Cyclic GMP-dependent protein kinase activation and induction by exisulind and CP461 in colon tumor cells. J Pharmacol Exp Ther. 2001 Nov;299(2):583-92.
5	Combined application of camptothecin and the guanylate cyclase activator YC-1: Impact on cell death and apoptosis-related proteins in ovarian carcinoma cell lines. Chem Biol Interact. 2009 Oct 7;181(2):185-92. doi: 10.1016/j.cbi.2009.05.013. Epub 2009 May 27.
6	Cyclic GMP mediates apoptosis induced by sulindac derivatives via activation of c-Jun NH2-terminal kinase 1. Clin Cancer Res. 2000 Oct;6(10):4136-41.